Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Conditions: Non-Small Cell Lung Cancer; RET Driver Mutation; BRAF V600 Mutation; Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation; MET Amplification; MET Exon 14 Skipping Mutation Interventions: Biological: Toripalimab; Drug: Nab paclitaxel; Drug: Pemetrexed; Drug: Carboplatin Sponsors: Guangdong Provincial People's Hospital; Shanghai Junshi Bioscience Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Hospitals | Immunotherapy | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Research